奥贝胆酸治疗熊去氧胆酸应答不佳原发性胆汁性胆管炎的真实世界纵向结局:联用贝特类药物的影响分层
这项纵向观察性多中心研究纳入西班牙和葡萄牙255例熊去氧胆酸应答不佳的原发性胆汁性胆管炎患者,评估奥贝胆酸联用或不联用贝特类药物的长期疗效。中位随访35.1个月,全队列12、24、36个月生化应答率分别为47.2%、61.4%和68.6%,三联疗法应答率显著高于二联疗法。
要点
- 全队列12、24、36个月生化应答率分别为47.2%、61.4%和68.6%。
- 三联疗法应答率显著高于二联疗法,包括碱性磷酸酶正常化、深度应答和生化缓解。
- 41.2%出现不良反应,18.8%因不良反应停用奥贝胆酸。
核心结论
- 在熊去氧胆酸应答不佳的原发性胆汁性胆管炎患者中,三联疗法在实现治疗目标方面优于二联疗法。
- 肝硬化患者失代偿与基线存在的门静脉高压相关。
研究设计与样本
- 纵向观察性多中心研究,纳入西班牙和葡萄牙的熊去氧胆酸应答不佳(Paris-II标准)原发性胆汁性胆管炎患者255例,接受奥贝胆酸联用或不联用贝特类药物治疗。
主要发现
- 中位随访35.1个月(IQR:20.2-53)。
- 全队列生化应答率在12、24和36个月分别为47.2%、61.4%和68.6%。
- GLOBE-PBC和5年UK-PBC评分改善(p < 0.001)。
- 三联疗法(熊去氧胆酸+奥贝胆酸+贝特类药物)应答率显著高于二联疗法(p = 0.001),包括碱性磷酸酶正常化、深度应答和生化缓解(p < 0.001)。
- 多因素分析中,三联疗法仍独立与生化应答相关(p = 0.024),与碱性磷酸酶正常化、深度应答和生化缓解相关(p < 0.001)。
关键数值与推荐
- 生化应答定义为碱性磷酸酶≤1.67倍正常上限,且较基线下降至少15%,同时胆红素水平正常。
- 深度应答定义为碱性磷酸酶正常化且胆红素≤0.6倍正常上限。
- 生化缓解定义为深度应答加转氨酶正常化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Suboptimal response to ursodeoxycholic acid occurs in 40% of primary biliary cholangitis (PBC) patients, affecting survival. Achieving a deep response (normalisation of alkaline phosphatase [ALP] and bilirubin ≤0.6 upper limit of normal) improves survival. Yet, the long-term effectiveness of second-line treatments remains uncertain. AIMS: To evaluate the long-term effectiveness of obeticholic acid (OCA) ± fibrates. Focusing on biochemical response (ALP ≤1.67 times the upper limit of normal, with a decrease of at least 15% from baseline and normal bilirubin levels), normalisation of ALP, deep response and biochemical remission (deep response plus aminotransferase normalisation). METHODS: We conducted a longitudinal, observational, multicentre study involving ursodeoxyccholic acid non-responsive PBC patients (Paris-II criteria) from Spain and Portugal who received OCA ± fibrates. RESULTS: Of 255 patients, median follow-up was 35.1 months (IQR: 20.2-53). The biochemical response in the whole cohort was 47.2%, 61.4% and 68.6% at 12, 24 and 36 months. GLOBE-PBC and 5-year UK-PBC scores improved (p < 0.001). Triple therapy (ursodeoxycholic acid plus OCA plus fibrates) had significantly higher response rates than dual therapy (p = 0.001), including ALP normalisation, deep response and biochemical remission (p < 0.001). In multivariate analysis, triple therapy remained independently associated with biochemical response (p = 0.024), alkaline phosphatase normalisation, deep response and biochemical remission (p < 0.001). Adverse effects occurred in 41.2% of cases, leading to 18.8% discontinuing OCA. Out of 55 patients with cirrhosis, 12 developed decompensation. All with baseline portal hypertension. CONCLUSION: Triple therapy was superior in achieving therapeutic goals in UDCA-nonresponsive PBC. Decompensation was linked to pre-existing portal hypertension.
引用
- Gómez E, Montero JL, Molina E, et al. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice. Aliment Pharmacol Ther. 2024. PMID: 38690746. doi:10.1111/apt.18004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。